Given the number of challenges that the industry is facing
Needham, MA (PRWEB) March 3, 2009
Cambridge Healthtech Institute announces its Premiere Collaborative Innovation in Biomedicine conference, to be held June 22-23, 2009 at the Marriott at Metro Center Hotel in Washington, DC. This conference is aimed at addressing some of the key challenges facing the pharmaceutical industry today, including, what has been described as the "Revenue Cliff" that the pharmaceutical industry faces, as a number of key patents expire on major drugs, as well as how the industry confronts the additional challenges of declining pipeline productivity, declining availability of R&D resources, and increasing regulatory and business practice pressures.
The program will focus on pre-competitive, consortia-based collaboration in drug discovery and development as a way of addressing major shared challenges within the industry, while sharing the cost for these solutions. "Given the number of challenges that the industry is facing," says Phillips Kuhl, President of Cambridge Healthtech Institute, "There is clearly a need for new models and approaches. Although this approach runs counter to some deeply entrenched attitudes within the industry, sharing best practices from past and current successful consortia provides a valuable approach for better understanding where this new model may be applied, and how they can be organized and managed for success."
The conference program will deal with such questions as how best to organize and manage these consortia, guidelines for data sharing, and how to effectively manage IP issues. The conference will feature speakers with first-hand experience in setting up and running successful consortia. Speakers will talk from first-hand experience about what works and what doesn't as the program explores the most important new models, key issues, challenges and best practices of Collaborative Innovation in Biomedicine.
Featured speakers include William Mattes, Ph.D., Director, Toxicology, Critical Path Institute; Jackie Hunter, Ph.D., Senior Vice President, GlaxoSmithKline; Arthur Holden, Chairman and Chief Executive Officer, Serious Adverse Events Consortium; Ken Buetow, Ph.D., Associate Director for Bioinformatics and Information Technology and Director of Center for Biomedical Informatics and Information Technology, National Cancer Institute and Co-founder, caBIG™ and The BIG Health Consortium™; Rebecca D. Kush, Ph.D., President and Chief Executive Officer, CDISC; Robert Porter Lynch, Chief Executive Officer, The Warren Company, Chairman Emeritus, The Association of Strategic Alliance Professionals, Inc. (ASAP); and Jessica Nadler, Ph.D., AAAS Fellow for Policy and Technology Policy, Department of Health and Human Services.
Case studies of emerging consortia-based models and best practices will be featured from such consortia as The Innovative Medicines Initiative, The Critical Path Institute, The Serious Adverse Events Consortium, Biomarkers Consortia, EMEA, The Dundee Kinase Consortia, and Drug Safety and Toxicology Consortia.
Please visit http://www.healthtech.com/cbi/overview.aspx for more information.
About Cambridge Healthtech Institute (CHI)
Founded in 1992, Cambridge Healthtech Institute (CHI) (http://www.chicorporate.com) is the industry leader offering the preeminent source of information to the leading researchers and business experts from top pharmaceutical, biotech, and academic organizations. Delivering an assortment of resources such as events, reports, publications and eNewsletters, CHI's portfolio of products include Cambridge Healthtech Institute Conferences, Barnett International, Insight Pharma Reports, Cambridge Marketing Consultants, Cambridge Meeting Planners, and Cambridge Healthtech Media Group.
Contact: Kaushik Chaudhuri
Cambridge Healthtech Institute